Tasly Holding Group is an internationalized and high-tech cooperation, engaging in pan-health industry.
Business Model: B2B
Revenue: $27.1M
Employees: 51-200
Address: 1 Research Ct
City: Rockville
State: MD
Zip: 20850
Country: US
Incorporated in 1994, Tasly Holding Group has now developed to an internationalized and high-tech cooperation, engaging in pan-health industry with biological medicine industry as the core business, health industry and medical service as two supporting businesses. Guided by Chinese ancient civilization, Tasly is devoted to the philosophy “seeking for harmonization between human and nature, improving humankind life quality” . With the mission of “to share the joy of health with all”, Tasly aims to become the No. 1 in modern biological pharmaceuticals and leader of integrated health industry in China. By now, Tasly has set up a pan-health industry line, which contains six core industries,including bio-pharmaceutical industry, health products industry, herbs industry, medical industry, health management industry and children education industry. Aiming to realize TCM globalization, Tasly has been sticking to develop the international market since its foundation. By now, more than 30 types of preparation products in 8 medical categories of Tasly have been put into the international market. And the export routes cover 23 countries in America, Europe, Africa and Asia. With the distribution network spreading to more than 40 countries, Tasly’s distributor members have almost reached a million in the world. In recent years, Tasly has been listed in the top 10 of TCM exporters in China. And in 2016, Tasly Pharm. Co.,Ltd was listed in the Top 500 of Chinese Enterprises released by the US Fortune magazine.
Contact Phone:
+13012163838
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
1/2020 | Zhangshang Tangyi | Series D | 144M |
12/2016 | AccuRad | Series B | 2.9M |
1/2018 | HOZ Medical | Angel Round | 8M |
10/2019 | Micot | Seed Round | 0 |
11/2016 | SHU LIAN YI KANG | Series A | 1.5M |
12/2017 | Genova | Corporate Round | 0 |
9/2017 | ZYBC | Angel Round | 0 |
5/2021 | Global Health Ark Medical Technology | Series A | 7.7M |
4/2017 | LenoMed Medical | Series A | 3.9M |
1/2018 | Shequ580 | Series A | - |
7/2017 | PegBio | Series E | 20M |
1/2022 | Hengyu Medical | Series C | - |
4/2020 | Avicanna | Post-IPO Equity | - |
1/2022 | Hengyu Medical | Series C | - |
5/2021 | Global Health Ark Medical Technology | Series A | 0 |
4/2020 | Avicanna | Post-IPO Equity | - |
1/2020 | Zhangshang Tangyi | Series D | 0 |
10/2019 | Micot | Seed Round | 0 |
1/2018 | HOZ Medical | Angel Round | 0 |
1/2018 | Shequ580 | Series A | - |
12/2017 | Genova | Corporate Round | 0 |
9/2017 | ZYBC | Angel Round | 0 |
7/2017 | PegBio | Series E | 0 |
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 5/2020 | Debt | $150k |
U.S. Small Business Administration. |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|